Mark Jeffrey Delong Sells 1,780 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 1,780 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total value of $39,498.20. Following the sale, the insider owned 83,058 shares in the company, valued at approximately $1,843,057.02. This trade represents a 2.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Apellis Pharmaceuticals Price Performance

Apellis Pharmaceuticals stock opened at $19.94 on Friday. The business’s fifty day moving average is $22.89 and its two-hundred day moving average is $23.41. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The firm has a market cap of $2.52 billion, a P/E ratio of 64.32 and a beta of 0.31. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $31.17.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The company had revenue of $458.58 million during the quarter, compared to analyst estimates of $364.58 million. During the same period last year, the company posted ($0.46) earnings per share. The firm’s quarterly revenue was up 133.0% compared to the same quarter last year. Equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

APLS has been the topic of several research analyst reports. HC Wainwright decreased their price target on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. The Goldman Sachs Group reaffirmed a “sell” rating and set a $19.00 price objective on shares of Apellis Pharmaceuticals in a report on Monday. Wall Street Zen raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. TD Cowen dropped their target price on Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Finally, Stifel Nicolaus decreased their price target on Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Eleven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $33.65.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in APLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Apellis Pharmaceuticals by 207.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,559 shares of the company’s stock worth $667,000 after purchasing an additional 19,944 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Apellis Pharmaceuticals by 26.6% in the first quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company’s stock valued at $6,730,000 after buying an additional 64,742 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Apellis Pharmaceuticals by 4.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company’s stock valued at $4,869,000 after buying an additional 9,747 shares during the period. Focus Partners Wealth boosted its holdings in Apellis Pharmaceuticals by 118.4% during the first quarter. Focus Partners Wealth now owns 21,883 shares of the company’s stock worth $479,000 after buying an additional 11,862 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of Apellis Pharmaceuticals by 1,146.2% during the 1st quarter. Acadian Asset Management LLC now owns 23,976 shares of the company’s stock worth $522,000 after buying an additional 22,052 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

Key Headlines Impacting Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo reiterated a Buy on Apellis, signaling continued confidence in the company’s longer‑term commercial execution and pipeline upside — a supportive voice for holders focused beyond near‑term sales. Read More.
• Positive Sentiment: Stifel Nicolaus issued a Buy on APLS (or reiterated constructive coverage), adding a second favorable analyst view that could help stabilize valuation if execution improves. Read More.
• Neutral Sentiment: Analysts remain mixed on Apellis: some see upside from Syfovre rollout and nephrology expansion while others emphasize near‑term sales risk and valuation — expect continued divergent research notes and volatile price reactions to company updates. Read More.
• Negative Sentiment: Apellis reported preliminary Q4 U.S. net product revenue of $190M and flagged weaker Syfovre sales with mixed Empaveli uptake — the main near‑term driver cited for a recent sharp weekly decline in the stock. Read More.
• Negative Sentiment: Major research houses (Cantor Fitzgerald, Needham) issued more pessimistic forecasts or lowered expectations, increasing downward pressure by reducing modeled revenues and price targets. Read More. Read More.
• Negative Sentiment: Significant insider selling on Jan. 13: multiple senior execs (CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others) sold shares at ~ $22.19 — filings show they still retain large stakes but the volume of disposals can be perceived negatively by the market. Read More.
• Negative Sentiment: Options flow indicated a large spike in put buying (reported >500% increase in put volume), reflecting elevated hedging and bearish positioning that can amplify short‑term volatility and downside pressure. Source: options flow reports

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.